Repetitive Transcranial Magnetic Stimulation and Acceptance and Commitment Therapy
NCT ID: NCT05427201
Last Updated: 2025-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
31 participants
INTERVENTIONAL
2023-05-22
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined TMS and Brief Cognitive Behavioral Therapy to Reduce Suicide
NCT03952468
rTMS for the Treatment of Chronic Pain in GW1 Veterans
NCT01608321
Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Improve Functioning
NCT03821337
rTMS for Tobacco Use in Veterans
NCT07050862
Efficacy of rTMS (Repetitive Transcranial Magnetic Stimulation) on Patients With Somatoform Pain Disorder
NCT00726791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ACT is an evidence-based psychosocial intervention that improves function in Veterans with chronic pain. However, similar to the broader literature, comorbid depression significantly limits the efficacy of ACT, which may be directly related to dysfunctional brain circuits that maintain depression. rTMS is a non-invasive brain stimulation intervention that is FDA-cleared for the treatment of depression. The most commonly targeted stimulation area is the left dorsolateral prefrontal cortex (DLFPC), a prefrontal brain region involved in cognitive control and emotion regulation. rTMS over the left DLPFC has also been used to reduce pain intensity in patients with chronic pain, as the DLPFC is implicated in the affective processing of painful stimuli. Importantly, while rTMS has been shown to reduce depression severity and pain intensity, it does not directly address function. Thus, the proposed research will integrate rTMS and ACT with the goal of maximizing functional improvement in Veterans with chronic pain and depression.
The purpose of this application is to examine the feasibility of a future randomized efficacy trial. A total of 24 Veterans with chronic pain and depression will be randomized into DLPFC-rTMS + ACT or sham-rTMS + ACT conditions. Multiple metrics of feasibility will be assessed, including general interest in the study, willingness to participate, enrollment, retention, drop-out, number of adverse events, and participant blindness to condition, as well as ratings of credibility, expectation, and treatment satisfaction. The investigators will also estimate the preliminary impact of DLPFC-rTMS + ACT and sham-rTMS + ACT on function as measured by reductions in pain interference (primary clinical outcome). The intent of preliminary analyses is to obtain an additional indicator for a future large-scale trial, not to verify group differences. Further, the investigators will include two cognitive control tasks, the Emotion Distractor and Attention-to-Breath tasks, with concurrent EEG recording as a potential objective indicator of treatment response. The study team has previously demonstrated the association between depression severity and DLPFC activity on these tasks. In the proposed study, the investigators will explore the associations between treatment-related change in DLPFC activity and treatment outcomes.
Veterans with chronic pain and depression do not have access to effective treatments. To address this need, the investigators seek to examine the feasibility of a novel approach by integrating a somatic and a psychosocial intervention. The investigator's scientific premise is that rTMS over the left DLPFC will remediate hypofunction of prefrontal brain circuits that is necessary to maximize the impact of ACT on function in Veterans with chronic pain and depression. Findings from the proposed research have the potential of substantially increasing the physical and psychosocial functioning of Veterans with chronic pain and depression.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DLPFC-rTMS + ACT
Active DLPFC-rTMS with ACT treatment
Repetitive Transcranial Magnetic Stimulation
rTMS is a non-invasive brain stimulation technique designed to alter network function
Acceptance and Commitment Therapy
ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
Sham-rTMS + ACT
Sham delivered rTMS with ACT treatment
Acceptance and Commitment Therapy
ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetitive Transcranial Magnetic Stimulation
rTMS is a non-invasive brain stimulation technique designed to alter network function
Acceptance and Commitment Therapy
ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Average pain intensity and interference with enjoyment of life and/or general activity rated \> 4/10 over the past week, as measured by the PEG
* Meet clinical criteria for major depression via DSM5 criteria, as assessed by the Mini International Neuropsychiatric Interview (MINI)
Exclusion Criteria
* Lifetime history of psychotic disorder, bipolar disorder, obsessive-compulsive disorder
* Active substance abuse or psychosocial instability (e.g., homelessness) that could compromise study participation
* Changes to professionally delivered pain or mood treatment (e.g., no discontinuation of a treatment; no increasing the dose of medication) one month preceding the baseline assessment
* Significant neurologic disorder, increased risk of seizure for any reason or family/personal history of seizure
* Contraindications to rTMS treatment as outlined by the Safety of TMS Consensus group, which includes implanted metallic objects above the neck, implanted electrical devices (pacemakers/spinal cord stimulators), and pregnancy
* Prior trial of rTMS for any condition and/or lack of responsiveness to electroconvulsive therapy
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew Herbert, PhD
Role: PRINCIPAL_INVESTIGATOR
VA San Diego Healthcare System, San Diego, CA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA San Diego Healthcare System, San Diego, CA
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RX004090
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
D4090-P
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.